In June 2023, LITFULO was approved to treat severe alopecia areata for ages 12+, and achieved #1 prescribed status in 2025 being the second JAK to launch in market. In 2026, there will be fierce competition within the JAK category for severe alopecia areata, with the expected launch of RINVOQ. The Consumer Senior Marketing Manager […]
